Skip to main content
. 2025 May 6;8:100171. doi: 10.1016/j.esmogo.2025.100171

Figure 4.

Figure 4

Kaplan–Meier estimates for immune checkpoint inhibitor (ICI)-based therapy according to the programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) status. (A) Progression-free survival (PFS) and (B) overall survival (OS) in ICI + chemotherapy (chemo). (C) PFS and (D) OS in nivolumab + ipilimumab (nivo + ipi). CI, confidence interval; ETS, early tumor shrinkage; NR, not reached.